

GERON CORPORATION  
Form 8-K  
January 22, 2003

**Table of Contents**

---

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 21, 2003**

**GERON CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**0-20859**  
(Commission File Number)

**75-2287752**  
(IRS Employer  
Identification Number)

**230 Constitution Drive  
Menlo Park, California**  
(Address of principal executive offices)

**94025**  
(Zip Code)

**(650) 473-7700**  
(Registrant's telephone number, including area code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

---

---

**TABLE OF CONTENTS**

Item 5. Other Events.

Item 7. Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events.**

On January 21, 2003, Geron Corporation, a Delaware corporation (the Company), announced that it is changing its organization in order to concentrate its resources on the continued development of its lead anti-cancer product, GRN163, and its regenerative medicine products based on human embryonic stem cells (hESCs). In the process, Geron is reducing its research staff by 29 employees and its support staff by 11 employees.

The Company's press release announcing the organizational change is filed as an exhibit to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the document filed as an exhibit hereto.

**Table of Contents**

**Item 7. Exhibits.**

**Exhibits**

99.1                      Press Release dated January 21, 2003.



**Table of Contents**

**EXHIBIT INDEX**

**Exhibits**

---

99.1                      Press Release dated January 21, 2003